---
schema_version: "secwatch.filing_event.v1"
accession: "0001819790-25-000120"
form_type: "8-K"
ticker: "TARS"
cik: "0001819790"
company_name: "Tarsus Pharmaceuticals, Inc."
filed_at: "2025-11-04T23:59:59+00:00"
generated_at: "2026-05-17T00:41:29.133787+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Tarsus Q3 2025: XDEMVY sales $118.7M, +147% YoY; net loss narrows to $0.30/share

## Summary
- XDEMVY net sales of $118.7M (Q3 2024: $48.1M); >103,000 bottles delivered to patients.
- Net loss of $12.6M vs $23.4M; diluted EPS $(0.30) vs $(0.61) in prior-year quarter.
- Cash, equivalents & marketable securities of $401.8M as of Sept 30, 2025.
- Phase 2 trial of TP-04 for ocular rosacea starting Dec 2025; Phase 2 of TP-05 for Lyme disease in 2026.

## SEC filing metadata
- accession: 0001819790-25-000120
- form_type: 8-K
- ticker: TARS
- cik: 0001819790
- company_name: Tarsus Pharmaceuticals, Inc.
- filed_at: 2025-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819790/000181979025000120/0001819790-25-000120-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819790/000181979025000120/tars-20251104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001819790-25-000120
- JSON: https://secwatch.observer/filing/0001819790-25-000120.json
- Plain text: https://secwatch.observer/filing/0001819790-25-000120.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.